Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NPF4: Variant p.Gly177Ala

tRNA N6-adenosine threonylcarbamoyltransferase
Gene: OSGEP
Feedback?
Variant information Variant position: help 177 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Alanine (A) at position 177 (G177A, p.Gly177Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In GAMOS3. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 177 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 335 The length of the canonical sequence.
Location on the sequence: help VGNCLDRFARVLKISNDPSP G YNIEQMAKRGKKLVELPYTV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         VGNCLDRFARVLKISNDPSPGYNIEQMAKRGKKLVELPYTV

Mouse                         VGNCLDRFARVLKISNDPSPGYNIEQMAKRGKKLVELPYTV

Rat                           VGNCLDRFARVLKISNDPSPGYNIEQMAKRGKKLVELPYTV

Bovine                        VGNCLDRFARVLKISNDPSPGYNIEQMAKRGKKLVELPYTV

Xenopus laevis                VGNCLDRFARVLKISNDPSPGYNIEQMAKKGKKFVELPYTV

Zebrafish                     VGNCLDRFARVIKISNDPSPGYNIEQMAKKGNKYIELPYTV

Drosophila                    VGNCLDRFARIIKLSNDPSPGYNIEQLAKSSNRYIKLPYVV

Slime mold                    VGNCLDRFARVIQIPNDPSPGYNIEQLAKKGKNLIELPYIT
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 335 tRNA N6-adenosine threonylcarbamoyltransferase
Binding site 162 – 162
Binding site 177 – 177
Binding site 181 – 181
Helix 176 – 184



Literature citations
Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly.
Braun D.A.; Rao J.; Mollet G.; Schapiro D.; Daugeron M.C.; Tan W.; Gribouval O.; Boyer O.; Revy P.; Jobst-Schwan T.; Schmidt J.M.; Lawson J.A.; Schanze D.; Ashraf S.; Ullmann J.F.P.; Hoogstraten C.A.; Boddaert N.; Collinet B.; Martin G.; Liger D.; Lovric S.; Furlano M.; Guerrera I.C.; Sanchez-Ferras O.; Hu J.F.; Boschat A.C.; Sanquer S.; Menten B.; Vergult S.; De Rocker N.; Airik M.; Hermle T.; Shril S.; Widmeier E.; Gee H.Y.; Choi W.I.; Sadowski C.E.; Pabst W.L.; Warejko J.K.; Daga A.; Basta T.; Matejas V.; Scharmann K.; Kienast S.D.; Behnam B.; Beeson B.; Begtrup A.; Bruce M.; Ch'ng G.S.; Lin S.P.; Chang J.H.; Chen C.H.; Cho M.T.; Gaffney P.M.; Gipson P.E.; Hsu C.H.; Kari J.A.; Ke Y.Y.; Kiraly-Borri C.; Lai W.M.; Lemyre E.; Littlejohn R.O.; Masri A.; Moghtaderi M.; Nakamura K.; Ozaltin F.; Praet M.; Prasad C.; Prytula A.; Roeder E.R.; Rump P.; Schnur R.E.; Shiihara T.; Sinha M.D.; Soliman N.A.; Soulami K.; Sweetser D.A.; Tsai W.H.; Tsai J.D.; Topaloglu R.; Vester U.; Viskochil D.H.; Vatanavicharn N.; Waxler J.L.; Wierenga K.J.; Wolf M.T.F.; Wong S.N.; Leidel S.A.; Truglio G.; Dedon P.C.; Poduri A.; Mane S.; Lifton R.P.; Bouchard M.; Kannu P.; Chitayat D.; Magen D.; Callewaert B.; van Tilbeurgh H.; Zenker M.; Antignac C.; Hildebrandt F.;
Nat. Genet. 49:1529-1538(2017)
Cited for: FUNCTION; CATALYTIC ACTIVITY; SUBCELLULAR LOCATION; IDENTIFICATION IN THE EKC/KEOPS COMPLEX; INVOLVEMENT IN GAMOS3; VARIANTS GAMOS3 PHE-14; GLU-78; MET-107; ARG-110; THR-111; THR-139; ALA-177; ARG-198; GLN-247; CYS-280; HIS-280; LEU-280; GLN-325 AND TRP-325; CHARACTERIZATION OF VARIANTS GAMOS3 PHE-14; ARG-110; THR-111; ARG-198; GLN-247; LEU-280 AND GLN-325;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.